Patents by Inventor Tie Wei

Tie Wei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250180585
    Abstract: Methods of detecting and flagging and/or suppressing aberrant results caused by incomplete dispersion of an immunoassay reagent used in a turbidimetric immunoassay are disclosed.
    Type: Application
    Filed: February 7, 2025
    Publication date: June 5, 2025
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventor: Tie Wei
  • Publication number: 20250147019
    Abstract: Biotin-trap compositions are disclosed that contain particles having an inner polymer coating layer disposed on at least a portion of an outer surface thereof and a biotin-specific binding partner conjugated to the inner polymer coating layer. The biotin-trap compositions may further include an outer polymer coating layer disposed about the biotin-specific binding partner. The biotin-trap compositions specifically bind to free biotin but do not substantially bind to biotin conjugated to other moieties, such as biotinylated assay reagents. Also disclosed are kits and microfluidics devices that include the biotin-trap compositions, as well as methods of producing and using the biotin-trap compositions.
    Type: Application
    Filed: December 16, 2022
    Publication date: May 8, 2025
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Zhu Teng, Jesse Spillane, Jie Li, Thomas Kennedy, Karen Krakowski, Izak Bahar, Tie Wei
  • Publication number: 20250147009
    Abstract: The present disclosure relates to methods and compositions to remove or reduce biotin interference from certain assays.
    Type: Application
    Filed: January 7, 2025
    Publication date: May 8, 2025
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Tie Wei, Zhu Teng, Izak Bahar
  • Publication number: 20250138011
    Abstract: Kits containing a multiplexed chemiluminescent detection system and microfluidics devices and methods for detecting the presence and/or concentration of anti-SARS-CoV-2 antibodies in a sample are disclosed. The kits, microfluidics devices, and methods utilize singlet oxygen-activatable chemiluminescent compounds in combination with two or more fluorescent molecules that emit light at different wavelengths. In certain non-limiting embodiments, the kits, microfluidics devices, and methods can distinguish between anti-SARS-CoV-2 antibodies generated in response to vaccination from anti-SARS-CoV-2 antibodies generated in response to infection.
    Type: Application
    Filed: August 25, 2022
    Publication date: May 1, 2025
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventor: Tie Wei
  • Patent number: 12259381
    Abstract: The present invention relates to methods and compositions to remove or reduce biotin interference from certain assays.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: March 25, 2025
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Tie Wei, Zhu Teng, Izak Bahar
  • Patent number: 12247987
    Abstract: Methods of detecting and flagging and/or suppressing aberrant results caused by incomplete dispersion of an immunoassay reagent used in a turbidimetric immunoassay are disclosed.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: March 11, 2025
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventor: Tie Wei
  • Publication number: 20240377406
    Abstract: Kits containing a multiplexed chemiluminescent detection system and microfluidics devices and methods for detecting the presence and/or concentration of biotin and at least one target analyte in a sample are disclosed. The kits, microfluidics devices, and methods utilize singlet oxygen-activatable chemiluminescent compounds in combination with two or more fluorescent molecules that emit light at different wavelengths.
    Type: Application
    Filed: July 24, 2024
    Publication date: November 14, 2024
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventor: Tie Wei
  • Publication number: 20240351033
    Abstract: Methods of mitigating lipoprotein interference in in vitro diagnostic assays for target hydrophobic analytes are disclosed, as well as compositions, kits, and devices useful in said methods. A pretreatment reagent is utilized that includes at least one enzyme that digests lipoprotein.
    Type: Application
    Filed: July 1, 2024
    Publication date: October 24, 2024
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Tie Wei, Jie Li, Yun Yue
  • Patent number: 12099055
    Abstract: The present invention relates to methods and compositions to remove or reduce biotin interference from certain assays.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: September 24, 2024
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventor: Tie Wei
  • Patent number: 12099063
    Abstract: Kits containing a multiplexed chemiluminescent detection system and microfluidics devices and methods for detecting the presence and/or concentration of biotin and at least one target analyte in a sample are disclosed. The kits, microfluidics devices, and methods utilize singlet oxygen-activatable chemiluminescent compounds in combination with two or more fluorescent molecules that emit light at different wavelengths.
    Type: Grant
    Filed: February 10, 2022
    Date of Patent: September 24, 2024
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventor: Tie Wei
  • Patent number: 12053775
    Abstract: Methods of mitigating lipoprotein interference in in vitro diagnostic assays for target hydrophobic analytes are disclosed, as well as compositions, kits, and devices useful in said methods. A pretreatment reagent is utilized that includes at least one enzyme that digests lipoprotein.
    Type: Grant
    Filed: May 12, 2022
    Date of Patent: August 6, 2024
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Tie Wei, Jie Li, Yun Yue
  • Publication number: 20240208996
    Abstract: The present disclosure includes compounds, kits, and assay procedures for use in determining the levels of certain types of drugs in samples that contain specific binding proteins for the drugs. The present disclosure includes analog compounds useful for displacing the drugs from their endogenous binding proteins, and kits including same, as well as methods that utilize these displacers as binding competitors in pharmaceutical assays.
    Type: Application
    Filed: March 12, 2024
    Publication date: June 27, 2024
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Tie Wei, Zhu Teng, Martin Drinan, Jie Li
  • Publication number: 20240168022
    Abstract: Reagents, kits, and microfluidics devices are disclosed for detecting the presence and/or concentration of antibodies directed to microorganisms in human biological samples. Also disclosed are methods of production and use of the reagents, kits, and microfluidics devices. Anti-human immunoglobulin antibodies are utilized as a reagent in a bridging immunoassay for detection of the microorganisms.
    Type: Application
    Filed: April 21, 2021
    Publication date: May 23, 2024
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventor: Tie Wei
  • Publication number: 20240159781
    Abstract: Methods are disclosed for a sandwich assay for a small molecule having a molecular weight of about 500 to about 2,500. The method comprises the use of a first antibody that binds to the small molecule and a second antibody that binds to the small molecule at a portion of the small molecule other than a portion to which the first antibody binds. The second antibody is prepared from an immunogen that comprises a hapten that is not the small molecule or a derivative of the small molecule wherein the hapten comprises a moiety that is structurally similar to that of the second portion of the small molecule. The antibodies may be employed in sandwich assays for the small molecule.
    Type: Application
    Filed: January 16, 2024
    Publication date: May 16, 2024
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventor: Tie Wei
  • Patent number: 11958863
    Abstract: The present disclosure includes compounds, kits, and assay procedures for use in determining the levels of certain types of drugs in samples that contain specific binding proteins for the drugs. The present disclosure includes analog compounds useful for displacing the drugs from their endogenous binding proteins, and kits including same, as well as methods that utilize these displacers as binding competitors in pharmaceutical assays.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: April 16, 2024
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Tie Wei, Zhu Teng, Martin Drinan, Jie Li
  • Patent number: 11913965
    Abstract: Methods are disclosed for a sandwich assay for a small molecule having a molecular weight of about 500 to about 2,500. The method comprises the use of a first antibody that binds to the small molecule and a second antibody that binds to the small molecule at a portion of the small molecule other than a portion to which the first antibody binds. The second antibody is prepared from an immunogen that comprises a hapten that is not the small molecule or a derivative of the small molecule wherein the hapten comprises a moiety that is structurally similar to that of the second portion of the small molecule. The antibodies may be employed in sandwich assays for the small molecule.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: February 27, 2024
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventor: Tie Wei
  • Publication number: 20230152318
    Abstract: Reagents, kits, and microfluidics devices are disclosed for detecting the presence and/or concentration of antibodies directed to microorganisms in human biological samples. Also disclosed are methods of production and use of the reagents, kits, and microfluidics devices. Anti-human immunoglobulin antibodies are utilized to enhance the signal produced by the assay.
    Type: Application
    Filed: April 21, 2021
    Publication date: May 18, 2023
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Tie Wei, Jie Li
  • Publication number: 20220387994
    Abstract: Methods of mitigating lipoprotein interference in in vitro diagnostic assays for target hydrophobic analytes are disclosed, as well as compositions, kits, and devices useful in said methods. A pretreatment reagent is utilized that includes at least one enzyme that digests lipoprotein.
    Type: Application
    Filed: May 12, 2022
    Publication date: December 8, 2022
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Tie Wei, Jie Li, Yun Yue
  • Publication number: 20220229049
    Abstract: Reagents for use in sandwich immunoassays for haptens are disclosed, along with kits containing same. Also disclosed are diagnostic immunoassay methods that utilize these immunoassay reagents in a particle enhanced agglutination detection assay for detecting haptens/drugs in samples.
    Type: Application
    Filed: October 25, 2019
    Publication date: July 21, 2022
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventor: Tie Wei
  • Publication number: 20220221448
    Abstract: The present invention relates to methods and compositions to remove or reduce biotin interference from certain assays.
    Type: Application
    Filed: March 18, 2022
    Publication date: July 14, 2022
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventor: Tie Wei